Analyst
Van Lanschot Kempen
Equibles does not estimate personal net worth.
Romy is recorded as Analyst at Van Lanschot Kempen. Romy has spoken on 2 earnings calls across 2 companies, most recently for Genmab A/S on May 7, 2026. Those appearances were for Genmab A/S (GMAB) and Zealand Pharma A/S (ZLDPF). The companies whose calls Romy spoke on are classified in the Healthcare sector.
“One on Upkinli, so looking ahead to the phase three readouts in first line. We recently did a survey which found that doctors are projecting Upkinli even before seeing this data to be the most dominant first line option.”
“The first, knowing now the progress of petrolintide to start phase three in the second half of the year, I was just wondering where ultimately you see petrolintide fitting into the general obesity market and more specifically within the amylin class based on the data we have to date.”
Van Lanschot Kempen
Analyst
Transcript header (unverified)
GMAB
Biotechnology · Healthcare
ZLDPF
Biotechnology · Healthcare
